South Carolina Clinic Leads Research on Promising Alzheimer's Drug
South Carolina Clinic Leads Research on Promising Alzheimer's Drug
US · Published Aug 1, 2026
Tribe Clinical Research, a clinic based in Greenville, South Carolina, is playing a key role in the development of a new drug targeting Alzheimer's disease.
The medication, named Remternetug, is designed to slow the progression of the disease by addressing an abnormal protein linked to Alzheimer's.

Impact & Risks

The development of Remternetug could have a significant impact on individuals and families affected by Alzheimer's disease. If successful, the drug may slow disease progression, allowing patients to maintain their independence for a longer period. However, the drug is still in the research phase, and its effectiveness and safety must be confirmed through clinical trials. The outcome of these trials will determine whether the drug can be approved by the FDA and made available to the public.

Related News